| abstract |
Described herein are the following compounds of Formula (I) or pharmaceutically acceptable salts thereof, methods of treating diseases susceptible to treatment with neurokinin antagonists using such compounds, and pharmaceutical compositions comprising the compounds :n n n Formula In n n n n n n n In the above formula,n n n Ar 1 and Ar 2 are optionally substituted heteroaryl or optionally substituted phenyl;n n n X 1 is —O—, —S—, —SO—, —SO 2 —, —NR 12 —, —NCOR 12 — or —NR 12 SO 2 R 15 —;n n n Is selected from the group consisting of:n n n n n n n n X 2 is -O-, -S- or -NR 5- ;n n n Y is = O, = S or = NR 11 ;n n n Y 1 is H, C 1 -C 6 alkyl, -NR 17 R 13, -SCH 3 , R 19 - aryl (CH 2) n6 -, R 19 - heteroaryl, - (CH 2) n6 -, - (CH 2 ) n6 -heterocycloalkyl ,-(C 1 -C 3 ) alkyl-NH-C (O) O (C 1 -C 6 ) alkyl or -NHC (O) R 15 ;n n n R 5 is H or - (CH 2), and n1 -G, n 1 is from 0 to 5, G is H, -CF 3, -CHF 2, -CH 2 F, -OH, -O- (C 1 - C 6 alkyl), -SO 2 R 13 , -O- (C 3 -C 8 cycloalkyl), -NR 13 R 14 , -SO 2 NR 13 R 14 , -NR 13 SO 2 R 15 , -NR 13 COR 12 , -NR 12 (CONR 13 R 14 ), -CONR 13 R 14 , -COOR 12 , C 3 -C 8 cycloalkyl, R 19 -aryl, R 19 -heteroaryl, provided that when n 1 is 0 G is not H;n n n R 1 , R 2 , R 3 and R 7 are H, alkyl, cycloalkyl, -CHF 2 , -CH 2 F or -CF 3 ; R 1 and R 2 together with the carbon to which they are attached form an alkylene ring; Or R 1 and R 2 together are ═O;n n n R 6 is R 7 or -OH;n n n The remaining variables are as defined herein.n n n Also described herein are pharmaceutical compositions comprising an effective amount of a compound of claim 1 and one or more pharmaceutically acceptable carriers in combination with an effective amount of a selective serotonin reuptake inhibitor. |